Caladrius Biosciences, Inc. (CLBS) Upgraded to “Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) from a hold rating to a buy rating in a report released on Wednesday. The firm currently has $3.25 target price on the biotechnology company’s stock.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Several other research analysts also recently weighed in on CLBS. HC Wainwright reaffirmed a buy rating and issued a $7.00 target price on shares of Caladrius Biosciences in a report on Friday, November 10th. ValuEngine raised shares of Caladrius Biosciences from a strong sell rating to a sell rating in a report on Friday, September 1st.

Shares of Caladrius Biosciences (NASDAQ:CLBS) opened at $3.50 on Wednesday. Caladrius Biosciences has a 12 month low of $2.63 and a 12 month high of $7.79.

Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 96.80%. research analysts anticipate that Caladrius Biosciences will post -2.33 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/19/caladrius-biosciences-inc-clbs-upgraded-to-buy-by-zacks-investment-research.html.

Institutional investors have recently modified their holdings of the stock. KCG Holdings Inc. boosted its holdings in Caladrius Biosciences by 74.6% in the 1st quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock worth $183,000 after buying an additional 15,501 shares during the period. Vanguard Group Inc. boosted its holdings in Caladrius Biosciences by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock worth $723,000 after buying an additional 4,163 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Caladrius Biosciences by 34.3% in the 1st quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock worth $491,000 after buying an additional 24,900 shares during the period. 6.36% of the stock is owned by institutional investors.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply